ArticleMMWR. Morbidity and mortality weekly report2014
Incidence of sickle cell trait--United States, 2010.
Article in MMWR. Morbidity and mortality weekly report, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 6 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Phenome- and laboratory-wide meta-analyses of sickle cell trait reveal multi-system disease associations.American journal of human genetics · 2026Pooled it
- Chronic kidney disease in adults with sickle cell trait: a systematic review and meta-analysis.Blood advances · 2025Pooled it
- Genetic Variation and Sickle Cell Disease Severity: A Systematic Review and Meta-Analysis.JAMA network open · 2023Pooled it
- Clinical Outcomes Associated With Sickle Cell Trait: A Systematic Review.Annals of internal medicine · 2018Pooled it
- Association of Sickle Cell Trait With Ischemic Stroke Among African Americans: A Meta-analysis.JAMA neurology · 2018Pooled it
- KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.Transplantation · 2017Guideline
- Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial.Journal of medical Internet research · 2019Trial
- Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease.Clinical pharmacokinetics · 2019Trial
- Reproductive Health CHOICES for Young Adults with Sickle Cell Disease or Trait: Randomized Controlled Trial Outcomes over Two Years.Journal of genetic counseling · 2016Trial
- Review
- Lower efficacy of transfusion of red blood cells from donors with sickle cell trait.HemaSphere · 2026Article
- Splenic Infarction Associated with Sickle Cell Trait: A Diagnosis Based on a Characteristic History of Climbing Mt. Fuji, with a Brief Literature Review.Internal medicine (Tokyo, Japan) · 2026Review
- Gynecologic and Reproductive Health in Patients with Sickle Cell Disease: Underrecognized Challenges and Care Management Opportunities.Journal of clinical medicine · 2026Review
- Silent sicklers and traumatic hyphema: the importance of maintaining a high index of suspicion.Digital journal of ophthalmology : DJO · 2026Article
- The differential expression of circulating microRNAs in sickle cell trait compared with the normal hemoglobin phenotype.Blood advances · 2025Article
- Risk factors associated with pain episodes among sickle cell patients that visited Mulago National Referral Hospital-Uganda.BMC health services research · 2025Article
- Cytokine and immune cell interaction in immune-inflammatory response during crisis event in sickle cell disease.African health sciences · 2025Article
- Splenic Infarction in a Patient With Sickle Cell Trait Following High-Altitude Exposure.Cureus · 2025Article
- Findings supporting neonatal screening for sickle cell disease: an observational study in Senegal.Frontiers in pediatrics · 2025Article
- Mitochondrial Dysfunction in Sickle Cell Trait Carriers With Exertional Collapse.Case reports in genetics · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persons with sickle cell trait (SCT) are heterozygous carriers of an abnormal ß-globin gene that results in the production of an abnormal hemoglobin, Hb S, which can distort red blood cells (http://www.cdc.gov/ncbddd/sicklecell/facts.html). All state newborn screening (NBS) programs have provided universal sickle cell disease (SCD) screening for newborns since 2006. Screening for SCD detects both SCD and SCT. To obtain up-to-date measures of the occurrence of SCT among newborns by race/ethnicity and state of birth, data collected by state NBS programs in 2010 were examined. In 2010, the incidence of SCT in participating states was 15.5 per 1,000 newborns overall; 73.1 among black newborns and 6.9 among Hispanic newborns. Incidence by state ranged from 0.8 per 1,000 screened newborns in Montana to 34.1 per 1,000 in Mississippi. Although the occurrence of SCT varies greatly from state-to-state and among different races and ethnicities, every state and racial/ethnic population includes persons living with the condition. The period immediately following NBS is ideal for primary care providers and genetic counselors to begin educating the families of identified persons with SCT about potential health complications and reproductive considerations.
Indexed as
Identifiers
25503918PMC4584538W21426482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.